Nivolumab-induced liver injury with a steroid-refractory increase in biliary enzymes, in a patient with malignant mesothelioma: An autopsy case report.

Nivolumab-induced liver injury with a steroid-refractory increase in biliary enzymes, in a patient with malignant mesothelioma: An autopsy case report.
复制标题

DOI:
10.1002/ccr3.5174
复制
发表时间:
2021-12
影响因子:
0.7
通讯作者:
Iwashita T
Iwashita T
中科院分区:
其他
文献类型:
--
作者:
Arai K;Matsuda M;Nakayasu H;Meguro S;Kurokami T;Kubota A;Iwasaki T;Suzuki M;Kawaguchi S;Iwashita T

文献摘要

参考文献

相似文献

这是nivolumab免疫治疗恶性间皮瘤的第一份肝毒性尸检报告。胆酶水平升高和随机分布的内皮损伤是类固醇难治性的,但由于恶病质放弃了二线治疗。需要进一步讨论免疫相关毒性的定制管理。需要进一步讨论以管理免疫相关肝毒性伴类固醇难治性胆酶升高和/或癌症并发症。今后,适合个人情况的管理将很重要。
This is the first autopsy report of hepatotoxicity from nivolumab immunotherapy for malignant mesothelioma. The increase in levels of biliary enzymes and randomly distributed endothelial damage were steroid‐refractory, but second‐line option was abandoned because of cachexia. Further discussions are needed regarding the customized management of immune‐related toxicities. Further discussions are needed to manage immune‐related hepatotoxicity with a steroid‐refractory increase in biliary enzymes and/or cancer complications. Management tailored to the conditions of individuals will be important in future.
DOI: 10.1016/j.jhep.2019.10.021
发表时间: 2020-02
影响因子: 25.7
作者:
Sangro B;Chan SL;Meyer T;Reig M;El-Khoueiry A;Galle PR
通讯作者: Galle PR
DOI: 10.1002/cld.653
发表时间: 2017-08-01
影响因子: --
作者:
Krishna, Murli
通讯作者: Krishna, Murli
DOI: 10.1016/s1470-2045(18)30828-3
发表时间: 2019-01-01
期刊: LANCET ONCOLOGY
影响因子: 51.1
作者:
Martins, Filipe;Sykiotis, Gerasimos P.;Obeid, Michel
通讯作者: Obeid, Michel
DOI: 10.1097/pas.0000000000000453
发表时间: 2015-08-01
影响因子: 5.6
作者:
Johncilla, Melanie;Misdraji, Joseph;Doyle, Leona A.
通讯作者: Doyle, Leona A.
DOI: 10.1016/j.isci.2020.101580
发表时间: 2020-10-23
期刊: iScience
影响因子: 5.8
作者:
Hu W;Wang G;Wang Y;Riese MJ;You M
通讯作者: You M